{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:21:42Z","timestamp":1793949702962,"version":"4.8.0"},"reference-count":51,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["I4V-UT-O005"],"award-info":[{"award-number":["I4V-UT-O005"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,5,8]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the effectiveness of a strategy administering baricitinib versus one using TNF-inhibitors (TNFi) in patients with rheumatoid arthritis (RA) after conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) failure in a real-life treat-to-target (T2T) setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with biological and targeted synthetic DMARD (b\/tsDMARD) na\u00efve RA with disease duration \u22645 years without contraindications to b\/tsDMARD were randomised to either TNFi or baricitinib when csDMARD failed to achieve disease control in a T2T setting. Changes in clinical and patient-reported outcome measures (PROMs) were assessed at 12-week intervals for 48 weeks. The primary endpoint was non-inferiority, with testing for superiority if non-inferiority is demonstrated, of baricitinib strategy in the number of patients achieving American College of Rheumatology 50 (ACR50) response at 12 weeks. Secondary endpoints included 28-joint count Disease Activity Score with C reactive protein (DAS28-CRP) &lt;2.6, changes in PROMs and radiographic progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 199 patients (TNFi, n=102; baricitinib, n=97) were studied. Both study groups were similar. Baricitinib was both non-inferior and superior in achieving ACR50 response at week 12 (42% vs 20%). Moreover, 75% of baricitinib patients achieved DAS28-CRP &lt;2.6 at week 12 compared with 46% of TNFi patients. On secondary outcomes throughout the duration of the study, the baricitinib strategy demonstrated comparable or better outcomes than TNFi strategy. Although not powered for safety, no unexpected safety signals were seen in this relatively small group of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Up to present, in a T2T setting, patients with RA failing csDMARDs have two main strategies to consider, Janus Kinases inhibitor versus bDMARDs (in clinical practice, predominantly TNFi). The PERFECTRA study suggested that starting with baricitinib was superior over TNFi in achieving response at 12 weeks and resulted in improved outcomes across all studied clinical measures and PROMs throughout the study duration in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004291","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T18:53:44Z","timestamp":1717095224000},"page":"e004291","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-1034","authenticated-orcid":false,"given":"Celine J","family":"van de Laar","sequence":"first","affiliation":[{"name":"Transparency in Healthcare BV, Hengelo, Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus Universiteit Rotterdam, Rotterdam, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn A H","family":"Oude Voshaar","sequence":"additional","affiliation":[{"name":"Department of Medical Cell BioPhysics & TechMed Center, University of Twente, Enschede, Overijssel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"ten Klooster","sequence":"additional","affiliation":[{"name":"Transparency in Healthcare bv @ University of Twente, Hengelo, Netherlands"},{"name":"Department of Technology, Human and Institutional Behaviour, University of Twente, Enschede, Overijssel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyta I","family":"Tedjo","sequence":"additional","affiliation":[{"name":"Transparency in Healthcare bv @ University of Twente, Hengelo, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Bos","sequence":"additional","affiliation":[{"name":"Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Frysl\u00e2n, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-3154","authenticated-orcid":false,"given":"Tim","family":"Jansen","sequence":"additional","affiliation":[{"name":"Rheumatology, VieCuri Medical Centre, Venlo, Limburg, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Willemze","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grada A","family":"Versteeg","sequence":"additional","affiliation":[{"name":"Rheumatology, Deventer Hospital, Deventer, Overijssel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y P M","family":"Goekoop-Ruiterman","sequence":"additional","affiliation":[{"name":"Rheumatology, HagaZiekenhuis, Den Haag, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric-Jan","family":"Kroot","sequence":"additional","affiliation":[{"name":"Rheumatology, Elkerliek Hospital, Helmond, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"van de Laar","sequence":"additional","affiliation":[{"name":"Transparency in Healthcare bv @ University of Twente, Hengelo, Netherlands"},{"name":"Department of Technology, Human and Institutional Behaviour, University of Twente, Enschede, Overijssel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"2025090312365497000_10.2.e004291.1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"The Lancet"},{"key":"2025090312365497000_10.2.e004291.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090312365497000_10.2.e004291.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2025090312365497000_10.2.e004291.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312365497000_10.2.e004291.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2025090312365497000_10.2.e004291.6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, Double\u2010Blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2025090312365497000_10.2.e004291.7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior Disease\u2010Modifying Antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2025090312365497000_10.2.e004291.8","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/keaa893","article-title":"Early phase studies of Jak1 selective inhibitors in rheumatoid arthritis","volume":"60","author":"Avci","year":"2021","journal-title":"Rheumatology"},{"key":"2025090312365497000_10.2.e004291.9","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2025090312365497000_10.2.e004291.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090312365497000_10.2.e004291.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"2025090312365497000_10.2.e004291.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510059"},{"key":"2025090312365497000_10.2.e004291.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090312365497000_10.2.e004291.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090312365497000_10.2.e004291.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080182"},{"key":"2025090312365497000_10.2.e004291.16","first-page":"S","article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (Das28)","volume":"32","author":"van Riel","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312365497000_10.2.e004291.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072"},{"key":"2025090312365497000_10.2.e004291.18","first-page":"261","article-title":"How to read Radiographs according to the sharp\/Van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025090312365497000_10.2.e004291.19","unstructured":"MDCG . MDCG 2021-6 Regulation (EU) 2017 \/ 745 \u2013 Questions & Answers Regarding Clinical Investigation. Medical Device Coordination Group, n.d.:2021."},{"key":"2025090312365497000_10.2.e004291.20","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-S1-A1"},{"key":"2025090312365497000_10.2.e004291.21","first-page":"725","article-title":"Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice","volume":"56","author":"Aaltonen","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312365497000_10.2.e004291.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.22193"},{"key":"2025090312365497000_10.2.e004291.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in Epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"2025090312365497000_10.2.e004291.24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for remission in rheumatoid arthritis patients: a systematic review","volume":"62","author":"Katchamart","year":"2010","journal-title":"Arthritis Care & Research"},{"key":"2025090312365497000_10.2.e004291.25","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","article-title":"Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor\u2013treated rheumatoid arthritis patients","volume":"58","author":"Hamann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312365497000_10.2.e004291.26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.23016","article-title":"Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti\u2013tumor necrosis factor","volume":"69","author":"Hamann","year":"2017","journal-title":"Arthritis Care & Research"},{"key":"2025090312365497000_10.2.e004291.27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E"},{"key":"2025090312365497000_10.2.e004291.28","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211415469"},{"key":"2025090312365497000_10.2.e004291.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"2025090312365497000_10.2.e004291.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025090312365497000_10.2.e004291.31","unstructured":"McKnight PE . The Corsini Encyclopedia of Psychology.2010. Available: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9780470479216"},{"key":"2025090312365497000_10.2.e004291.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.20204"},{"key":"2025090312365497000_10.2.e004291.33","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/sja.SJA_559_18","article-title":"The CONSORT statement","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2025090312365497000_10.2.e004291.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"Zwarenstein","year":"2008","journal-title":"BMJ"},{"key":"2025090312365497000_10.2.e004291.35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1744666X.2022.2064275","article-title":"Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis","volume":"18","author":"Venetsanopoulou","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312365497000_10.2.e004291.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203497"},{"key":"2025090312365497000_10.2.e004291.37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/03009742.2015.1043142","article-title":"Impact of physicians adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACO trial","volume":"44","author":"Kuusalo","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2025090312365497000_10.2.e004291.38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"The Lancet"},{"key":"2025090312365497000_10.2.e004291.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200274"},{"key":"2025090312365497000_10.2.e004291.40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-016-3191-3","article-title":"Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM Registry","volume":"35","author":"Steunebrink","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312365497000_10.2.e004291.41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3B\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"The Lancet"},{"key":"2025090312365497000_10.2.e004291.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"2025090312365497000_10.2.e004291.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2025090312365497000_10.2.e004291.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218412"},{"key":"2025090312365497000_10.2.e004291.45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10067-014-2538-x","article-title":"Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker","volume":"33","author":"Siemons","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025090312365497000_10.2.e004291.46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000382","article-title":"Das28-CRP and Das28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2025090312365497000_10.2.e004291.47","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"},{"key":"2025090312365497000_10.2.e004291.48","unstructured":"EMA . EMA Recommends Measures to Minimise Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders. European Medicines Agency, Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic [accessed 4 Aug 2023]."},{"key":"2025090312365497000_10.2.e004291.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.010"},{"key":"2025090312365497000_10.2.e004291.50","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"2025090312365497000_10.2.e004291.51","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain","year":"2021","journal-title":"Cureus"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:37:08Z","timestamp":1756928228000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/rmdopen-2024-004291"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004291","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}